Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a morphine derivative structurally similar to dopamine that is used in the treatment of motor fluctuations in Parkinson's disease and erectile dysfunction. The use of apomorphine to induce vomiting in poisoning is ruled out. Subcutaneous or sublingual administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very high percentage of protein binding, very wide volume of distribution and short half-life) make it highly unlikely that significant quantities will pass into breast milk.
Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
Likely side effects are nausea and vomiting.